SCHEMBL19220793

SCHEMBL19220793

COc1cc2c(Nc3ccc(F)c(C)c3)ncnc2cc1OCCN1CCCC1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 11/20 0.82
KDR P35968 7/20 0.74
EPHB4 P54760 3/20 0.74
EPHA2 P29317 2/20 0.74
RET P07949 5/20 0.71
FGFR1 P11362 1/20 0.71
FLT1 P17948 1/20 0.71
CIT O14578 1/20 0.64
GAK O14976 1/20 0.64
EPHB6 O15197 1/20 0.64
ABCC4 O15439 1/20 0.64
DAPK3 O43293 1/20 0.64
RIPK2 O43353 1/20 0.64
NR1I2 O75469 1/20 0.64
RPS6KA4 O75676 1/20 0.64
STK17B O94768 1/20 0.64
STK10 O94804 1/20 0.64
PRKD3 O94806 1/20 0.64
ABCB11 O95342 1/20 0.64
MAP4K4 O95819 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19220796 0.95 EGFR (0.82) EGFRKDREPHB4EPHA2RET
SCHEMBL19220798 0.95 EGFR (0.78) EGFRKDREPHB4EPHA2RET
SCHEMBL11132 0.90 EGFR (1.00) EGFRKDREPHB4EPHA2RET
SCHEMBL17520332 0.90 EGFR (1.00) EGFRKDREPHB4EPHA2RET
SCHEMBL8669 0.89 EGFR (1.00) EGFRKDREPHB4EPHA2RET
SCHEMBL799681 0.88 EGFR (0.83) EGFRKDREPHB4EPHA2RET
SCHEMBL12012 0.86 EGFR (1.00) EGFRKDREPHB4EPHA2RET
SCHEMBL17520338 0.86 EGFR (1.00) EGFRKDREPHB4EPHA2RET
SCHEMBL25707230 0.86 RET (0.68) EGFRKDREPHB4RETRIPK2
SCHEMBL907931 0.85 KDR (1.00) EGFRKDREPHB4EPHA2ERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170226099-A1 QUINAZOLINE DERIVATIVE CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) 2017-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170226099-A1 QUINAZOLINE DERIVATIVE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TOP2A, TOP1 EGFR 3701/4885KDR 3669/4885EPHB4 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.